The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AUTOLUS THERAPEUTICS PLC | SPON ADS | 05280R100 | 26,021 | 2,095,127 | SH | DFND | 2 | 0 | 0 | 0 | |
| EVOFEM BIOSCIENCES INC | Common | 30048L104 | 16,923 | 3,357,718 | SH | DFND | 2 | 0 | 3,357,718 | 0 | |
| EVOFEM BIOSCIENCES INC | Common | 30048L104 | 46,058 | 9,138,504 | SH | DFND | 1 | 0 | 9,087,206 | 51,298 | |
| THERAVANCE BIOPHARMA INC | Common | G8807B106 | 204,371 | 10,491,349 | SH | DFND | 1 | 0 | 10,491,349 | 0 | |
| THERAVANCE BIOPHARMA INC | Common | G8807B106 | 16,741 | 859,370 | SH | DFND | 0 | 859,370 | 0 | ||